HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INNV
InnovAge Holding Corp.
INNV's fundamentals are strong: revenue grew 15% and its operating margin went from −1.9% to 1.4%. At 157x earnings, it's trading above its usual 87x. Analysts expect that strong growth to continue.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INNV Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
INNV's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INNV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $9.40 | — |
| Cheap | 44x | $2.62 | -72% |
| Fair | 87x | $5.22 | -44% |
| Expensive | 150x | $8.97 | -4.6% |
| Current | 157x | $9.40 | — |
Historical ranges are pointers, not guarantees.
INNV's PE is in its expensive range at 157x. If earnings grow as analysts expect, today's price would be 21x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INNV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
INNV has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INNV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.45 | +655% |
| Q3 2026 | $0.06 | +$0.18 |
| Q2 2026 | -$0.02 | +$0.20 |
| Q1 2026 | -$0.08 | +$0.15 |
| Q4 2025 | $0.06 | +$0.25 |
| Q3 2025 | -$0.12 | $0.00 |
| Q2 2025 | -$0.22 | -$0.06 |
| Q1 2025 | -$0.23 | $0.00 |
| Q4 2024 | -$0.19 | +$0.05 |
INNV has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INNV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
INNV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $264.8M | +12% |
| Q2 2026 | $262M | +18% |
| Q1 2026 | $251.9M | +15% |
| Q4 2025 | $239.7M | +15% |
| Q3 2025 | $236.1M | +15% |
| Q2 2025 | $221.4M | +11% |
| Q1 2025 | $218.1M | +13% |
| Q4 2024 | $209M | +11% |
INNV's revenue has grown year over year for 14 quarters in a row: $265M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.6% | +4.1 points |
| Q2 2026 | 3.9% | +4.8 points |
| Q1 2026 | -12% | -6.9 points |
| Q4 2025 | 5.5% | +12 points |
| Q3 2025 | 3.5% | +5.9 points |
| Q2 2025 | -1% | +1.5 points |
| Q1 2025 | -4.7% | -1.7 points |
| Q4 2024 | -6% | -5.1 points |
INNV has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
INNV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.8M | +$25.9M |
| Q2 2026 | $17M | +85% |
| Q1 2026 | $14.5M | -33% |
| Q4 2025 | $19M | +251% |
| Q3 2025 | -$153K | +$9.6M |
| Q2 2025 | $9.2M | +$10.6M |
| Q1 2025 | $21.7M | +611% |
| Q4 2024 | $5.4M | +$16.3M |
INNV generated $76M in free cash flow over the past year, up 111% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INNV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INNV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1.4M shares |
| 1 year | +0.2% | +308K shares |
| 3 years | +0.9% | +1.3M shares |
| 5 years | +1.1% | +1.6M shares |
| Available history | +1.2% | +1.6M shares |
INNV has 137M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $77.6M |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INNV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.0x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -4.4x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -3.1x | Net Cash |
| Q3 2024 | 9.3x | High |
| Q2 2022 | -11.8x | Net Cash |
| Q1 2022 | -4.0x | Net Cash |
INNV has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INNV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 20.7 | Neutral |
INNV's weekly RSI is 50 (neutral) and its Stochastic is 21 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INNV PE vs Healthcare Sector
| Metric | INNV | Sector median | Relative |
|---|---|---|---|
| PE | 157x | 26x | 506% above |
| PE % | 90 | 35 | 55 pts above |
INNV is trading at 157x earnings, a 506% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INNV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.13 | 3% above |
| 20 week MA | $10.4 | 9.2% below |
| 50 week MA | $8.59 | 9.4% above |
| 100 week MA | $6.26 | 50% above |
| 200 week MA | $6.08 | 55% above |
INNV has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INNV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.1 | $5.31 | -78% |
| 2022 | $5.31 | $6.85 | +29% |
| 2023 | $6.85 | $6.00 | -12% |
| 2024 | $6.00 | $3.92 | -35% |
| 2025 | $3.92 | $5.54 | +41% |
| 2026 YTD | $5.54 | $9.40 | +70% |
INNV has the edge over HIMS on returns for 2026, with the stronger performance.